Yantai Dongcheng Pharmaceutical Group Co.

Yantai Dongcheng Pharmaceutical Group Co.

Yantai Dongcheng Pharmaceutical Group Co. was founded in 1998 in Yantai, Shandong province, and listed on the Shenzhen Stock Exchange in May 2012 under ticker 002675. Chairman Youyu Shouyi built the firm from a biochemical raw material supplier into a fully integrated pharmaceutical enterprise with four business segments: biochemical API, chemical drugs, traditional Chinese medicine, and nuclear medicine. The company's strategy spans raw-material production, drug R&D, manufacturing, and sales. It operates two major divisions — chemical drugs and nuclear medicine — with products exported to more than 40 countries. Key asset classes include API manufacturing, formulation development, and radiopharmaceutical pipeline. Notable recent milestone: in January 2026, its subsidiary Lanacheng received Chinese NMPA acceptance of a New Drug Application for fluro-[18F]-seride injection, a PSMA-targeted PET imaging agent for prostate cancer (per firm website, January 2026). Geographic coverage focuses on China, with additional operations in South Korea, Taiwan, and Shanghai. The group employs roughly 3,000 people and runs dedicated research platforms, a Yantai Nuclear Medicine Science Museum, and separate business segments for raw materials, formulations, nuclear products, and health products. It was recognized by the China Building Decoration Association with the 15th China Space Design Gold Award for the Nuclear Medicine Museum in February 2026. Its philanthropic arm includes social welfare and safety initiatives under the 'Responsibility Dongcheng' banner. A structural differentiator is Dongcheng's full vertical integration from upstream biochemical raw heparin (API) through to advanced radiopharmaceuticals — a rare span in Chinese pharma. The company operates both as a generic API exporter and a developer of proprietary nuclear imaging drugs, giving it a dual revenue base uncommon among Chinese listed drugmakers.